Dr. Dong Dong Full Biography
Biography
Driven by a commitment to justice, equity, and intersectionality within public health, Dr. Dong embodies an interdisciplinary approach. Her background in communication and epidemiology fuels her belief that complex public health challenges require collaborative, cross-disciplinary action. Her work integrates social science perspectives to complement health sciences, focusing on how social dynamics shape health experiences. Dr. Dong employs a wide array of methodologies, including meta-ethnography, multi-sited ethnography, in-depth interviews, extended case studies, cross-sectional surveys, patient registries, Q methodology, patient journey analysis, and studies of the natural history of rare diseases, adapting them to the needs of public health research. To ground her research, she cultivates close, long-term relationships with underprivileged and underserved populations, recognizing them as central to knowledge creation. Dr. Dong has been awarded 65 grants to date, 32 as Principal Investigator (PI) and 33 as Co-Investigator, totaling US$19.43 million (US$2.05 million as PI/PC). More than a third of her 100+ SCIE/SSCI-indexed journal articles focus on rare diseases, alongside her extensive contributions to white papers, conference proceedings, and four published books.
A people-centered approach is central to Dr. Dong’s research. She pioneers community-academic partnerships, a nascent field in both Hong Kong and Mainland China. Rare diseases are a recurring focus. Departing from the typical biomedical view of disablement, she explores the possibilities inherent in the rare disease experience. Her work includes developing large-scale patient registry databases in China, which serve to illuminate the medical and social conditions of patients, monitor their quality of life, and evaluate the effectiveness of interventions. In Hong Kong, her work with multicultural communities has brought forth crucial questions of communicative injustice and discrimination in the health experiences of South Asians, often explored through a gendered lens. Dr. Dong’s recent research also delves into the science and technology of reproductive health and genetic literacy, investigating how the interplay between state discourse, genetic technology, and informed consent shapes bio-power and raises critical bioethical concerns.
Dr. Dong’s collaborative work with patients, NGOs, grassroots organizations, medical professionals, anthropologists, and sociologists has contributed to policy advancements at the national and international levels. As a leader in the World Mental Health International College Student Initiative, she is a member of the Qualitative Research Workgroup's steering committee, contributing her expertise to this global collaboration. Dr. Dong founded a Rare Disease Real-world Data Lab in Shenzhen Research Institute, CUHK, producing over twenty white papers on the General Social Survey of Chinese Patients with Rare Diseases. She also serves on the boards of the Asian Pacific Alliance of Rare Disease Organisations (APARDO), China Alliance for Rare Diseases, Beijing Society of Rare Disease Clinical Care and Accessibility, The Illness Challenge Foundation, and Beijing Aili Myasthenia Gravis Care Center. Furthermore, she is a foreign member of the MGNet Rare Disease Clinical Research Consortium and the Rare Diseases Clinical Research Network of the National Institute of Health in the U.S.A.. Dr. Dong is a recipient of the 2022 Equity Initiative Fellowship and currently serves as a Global Senior Fellow of the Atlantic Institute. Her work on socio-economic burdens in public health, patient narratives, and cross-cultural observations on illness has been featured extensively in the media.
Education
- Ph.D.
- Major: Mass Communication, Minor: Epidemiology, University of Minnesota, Twin Cities
- M.Phil.
- Mass Communication, The Chinese University of Hong Kong
- B.A.
- Journalism, Fudan University
Professional Experience
Current academic position
Assistant Professor, JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, 09/2021-present
Other affiliations
- Associate, Department of Psychology, Faculty of Arts and Sciences, Harvard University, 3/2024 – present
- Research Fellow (by courtesy), CUHK Centre for Bioethics, The Chinese University of Hong Kong, 11/2023-present
- Director, Rare Disease Real-world Data Lab, Shenzhen Research Institute, The Chinese University of Hong Kong, 7/2020-present
- Associate Research Fellow (by courtesy), Shenzhen Research Institute, The Chinese University of Hong Kong, 09/2018-present
- Key Member, Centre for Health Systems and Policy Research, The Chinese University of Hong Kong, 09/2018-present
Professional Societies
- Member of Steering Committee & Lead investigator, The World Mental Health International College Student (WMH-ICS) Initiative- Qualitative Project, 2024-present
- Atlantic Fellow for Health Equity, China Medical Board and The Atlantic Philanthropies, 2023-present
- Member of Standing Committee, Rare Disease Sub-Committee, Chinese Hospital Association, 2022-present
- Member, MGNet Rare Disease Clinical Research Consortium, USA, 2019-present
- Member, The Coalition for Patients Advocacy Groups (CPAG), the Rare Diseases Clinical Research Network (RDCRN), National Institute of Health, USA, 2019-present
Selected publications
International journal publications related to rare diseases
(# co-first author; *corresponding author)
- Xu, R.H., Zhang, H., Chen, S., Yu, J., Zhang, S., & Dong, D.* (2025). The impact of social support on the quality of life of patients with myasthenia gravis: A cross-sectional study in China. Orphanet Journal of Rare Diseases, 20(1), 1-12.
- Yu J, Chen S, Zhang H, Zhang S*, Dong D* (2024). Patterns of the Health and Economic Burden of 33 Rare Diseases in China: Nationwide Web-Based Study. JMIR Public Health and Surveillance. 2024 Aug 27;10(1):e57353.
- Xu, R. H., Zhao, Z., Mao, Z., Wang, S., Xiong, H., & Dong, D.* (2024). Measurement properties of the EQ-5D-Y-3L, PedsQL 4.0, and PROMIS-25 Profile v2. 0 in pediatric patients with spinal muscular atrophy. Health and Quality of Life Outcomes, 22(1), 50.
- Yu, J., Xie, L., Chen, S., Fang, ZL., Zhu LL., Zhang HY., Xu RH., Yang, H., & Dong. D.* (2024). Social support and medication adherence among adult myasthenia gravis patients in China: the mediating role of mental health and self-efficacy. Orphanet Journal Rare Diseases, 19, 143. https://doi.org/10.1186/s13023-024-03145-6
- Xu, R.H., Luo, N., & Dong, D.* (2024). Measurement properties of the EQ‑5D‑3L, EQ‑5D‑5L, and SF‑6Dv2 in patients with late‑onset Pompe disease. European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01682-2 (IF 2022: 4.4, Rank 12/87 (86.8%), Q1, in Health Policy & Services-SSCI; Rank 71/380 (81.4%), Q1, in Economics – SSCI, Time cited:0)
- Chen, S., Zhang, H., Yu, J., Cao, X., Zhang, S., & Dong, D.* (2024). Economic Burden of Huntington’s Disease in China: Results from a National-Wide Cross-Sectional Study. Neuroepidemiology, 58(1), 31-36. DOI: 10.1159/000534564
- Xu, R. H., Ma, B., Xin, H., Zhang, H., Zeng, Y., Luo, N., & Dong, D.* (2023). Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy. Health and Quality of Life Outcomes, 21(1), 123.
- Xu, R.H., Zhu, L., Sun, R., Zou SN., & Dong, D.* (2023) Impact of caregiver’s eHealth literacy, financial well-being, and mental health on quality of life of pediatric patients with osteogenesis imperfecta. Health and Quality of Life Outcomes 21, 67. https://doi.org/10.1186/s12955-023-02148-4
- Barnett, C., Alzahmi, F., Dong, D., Heckman, J., Salutto, V., & Shin, H. Y. (2023). Challenges managing myasthenia gravis: an international perspective. RRNMF Neuromuscular Journal, 4(3). DOI: https://doi.org/10.17161/rrnmf.v4i3.19553
- Fang, Z., Liu, G., Zhu, L., & Dong, D*. (2023). Doing “gendered exit”: Work, care and the moral practices of disabled persons. Gender, Work & Organization. 1-14. DOI: 10.1111/gwao.12990
- Xu, R.H., Dai, Y., Ng, S.S.M., Tsang, HWH, Zhang SY, & Dong D*. (2023) Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy. https://doi.org/10.1007/s10198-023-01574-x. European Journal of Health Economics . Xu, R.H., Lu, M., Zhang, SY*, and Dong, D.* (2023). EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy. European Journal of Health Economics, 24, 1399–1410. https://doi.org/10.1007/s10198-022-01551-w
- Xu, R. H., Dai, Y., Ng, S. S., Zhang, S., & Dong, D.* (2023). Health-related quality of life in children and adolescents with Duchenne muscular dystrophy and comorbid attention-deficit hyperactivity disorder using propensity-score matching. Journal of Affective Disorders, 333, 147-153. https://doi.org/10.1016/j.jad.2023.04.036
- Zhang, H, Chen, S and Dong, D.* (2022) Association of migration status with quality of life among rural and urban adults with rare diseases: A cross-sectional study from China. Frontiers in Public Health 10:1030828. doi: 10.3389/fpubh.2022.1030828 .
- Chen, S., and Dong, D*. (2022). Improving insurance protection for rare diseases: economic burden and policy effects—simulation of people with Pompe disease in China. International Journal of Health Policy and Management, https://dx.doi.org/10.34172/ijhpm.2022.6282.
- Xu RH, Yu S, Liu J, Zhang SY, Dong D.* (2022) Developing the health state classification system for a condition-specific preference-based measure for patients with myasthenia gravis, Disability and Rehabilitation, DOI: 10.1080/09638288.2022.2120096
- Xu RH., Zhu LL., Sun RJ., Tan RLY., Luo N., Zou SN., Dong D*. (2022) Investigating the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, CHU-9D, and PedsQL in Children and Adolescents with Osteogenesis Imperfecta. European Journal of Pediatrics. 2022 Dec;181(12):4049-4058. doi: 10.1007/s00431-022-04626-1
- Chen S, Wang Y, Zhu L, Gan Y, Dong D* (2022). Factors associated with the psychological quality of life among adolescents with rare diseases in China: a national repetitive cross-sectional study. Social Psychiatry and Psychiatric Epidemiology. 2022, Apr 11. doi: 10.1007/s00127-022-02286-y.
- Zhang H., Xiao Y., Zhao X., Tian Z., Zhang SY*, Dong D* (2022). Physicians’ knowledge on specific rare diseases and its associated factors: a national cross-sectional study from China. Orphanet Journal of Rare Diseases, 17, 120. https://doi.org/10.1186/s13023-022-02243-7 .
- Chen S, Wang Y, Zhu L, Feng Z, Gong S, Dong D* (2022). Social activity as mediator between social support and psychological quality of life among people with rare diseases: A national repetitive cross-sectional study, Journal of Psychiatric Research (2022), doi: https://doi.org/10.1016/j.jpsychires.2022.03.042.
- Xu, RH#, Dong D.#*, Luo N., Wong, ELY, Yang, RC, Liu JS, Yuan, HQ, and Zhang SY*. (2021). Mapping the Haem-A-QoL to the EQ-5D-5L Utility Scores in among Patients with Hemophilia. Quality of life Research.
- Wang K, Guo X, Yu S, Gao L, Wang Z, Zhu H, Xing B*, Zhang S* and Dong D* (2021) Patient-Identified Problems and Influences Associated with Diagnostic Delay of Acromegaly: A Nationwide Cross-Sectional Study. Frontiers in Endocrinology 12:704496. doi: 10.3389/fendo.2021.704496
- Xu, RH#, Dong D.#*, Luo N., Yang, RC, Liu JS, and Zhang SY*. (2021). Investigating the added value of the EQ-5D-5L with two bolt-on items in patients with hemophilia. Frontiers in Medicine. https://doi.org/10.3389/fmed.2021.707998
- Wang KL, Guo XP, Yu SY, Gao L, Wang ZH, Zhu HJ, Xing B*, Zhang SY*, Dong D* (2021). Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly. European Journal of Health Economics. 2021 Dec;22(9):1381-1391. doi: 10.1007/s10198-021-01318-9
- Chen, SQ., Wang, JX., Zhu, JF., Chung RYN, and Dong, D.* (2021). Quality of life and its contributors among adults with late-onset Pompe disease in China. Orphanet Journal of Rare Diseases. 16 (199). https://doi.org/10.1186/s13023-021-01836-y.
- Xu, RH#, Dong, D.#*, Luo N., Wong, ELY, Wu YS, Yu, SY, Yang, RC, Liu, JS, Yuan, HQ, Zhang, SY*(2021). Evaluating the Psychometric Properties of the EQ-5D-5L and SF-6D among Patients with Haemophilia. European Journal of Health Economics. 2021 Jun;22(4):547-557. doi: 10.1007/s10198-021-01273-5
- Guo XP, Wang KL, Yu SY, Gao L, Wang ZH, Zhu HJ, Xing B*, Zhang SY*, Dong D* (2020). Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa750
- Dong D., Chung RYN, Chan R, Gong SW, and Xu H. (2020). Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China. Orphanet Journal of Rare Diseases. 15, 307 (2020). https://doi.org/10.1186/s13023-020-01587-2
- Dong D., Chong KC, Wu YS, Kaminski H, Cutter G, Xu XH, Li HF, Zhao CB, Yin J. Yu SY, and Zhu JF. (2020). Gender Differences in Quality of Life among Patients with Myasthenia Gravis in China. Health and Quality of Life Outcomes doi: 10.1186/s12955-020-01549-z
- Gong SW, Li DH, and Dong. D.* (2020). How do patients and doctors perceive medical services for rare diseases differently in China? Insights from two national surveys. International Journal of Environmental Research and Public Health, 17, 1757. doi: 10.3390/ijerph17165961
- Yan X., Dong D., He SJ, and Webster CJ. (2020). Examining trans-provincial diagnosis of rare diseases in China: The importance of healthcare resource distribution and patient mobility. Sustainability.
- Dong, D., Jin, J., Oerlemans, S. et al. (2020) Validation of the Chinese EORTC chronic lymphocytic leukemia module – application of classical test theory and item response theory. Health and Quality of Life Outcomes 18, 96 (2020). https://doi.org/10.1186/s12955-020-01341-z
- Yan, X.; He, S.; Dong, D*. (2020). Determining How Far an Adult Rare Disease Patient Needs to Travel for a Definitive Diagnosis: A Cross-Sectional Examination of the 2018 National Rare Disease Survey in China. International Journal of Environmental Research and Public Health 2020, 17, 1757.
- Dong D.* & Wang Y. (2016). Challenges of rare diseases in China. The Lancet, 387(10031), 1906. doi: 10.1016/s0140-6736(16)30418-4.
Selected books related to rare diseases
- Yan Chuanzhu, Zhao Kun, and Zhao Chongbo (Chief Editors), Hu Xin and Dong Dong (Associate Editors), Rare Disease Prevention, Treatment, and Protection in China: Myasthenia Gravis, Beijing: People’s Medical Publishing House, (2024). (in Chinese).
- Zhang Shuyang and Dong Dong. 2020 General Social Survey of Rare Diseases in China. Beijing: People’s Medical Publishing House, 2020. (in Chinese)
Selected invited presentations/lectures on rare disease
- Dong D. (July 24, 2024). Disease management and quality of life among SMA patients in China: Findings based on Meier SMA patient registry. The 2024 Clinical Pharmacy Innovation and Development Forum Series on Pediatric Clinical Services and Pharmacy Research Academic Salon, Shanghai, China. Invited by the Clinical Pharmacy Department of Shanghai Jiao Tong University School of Medicine Affiliated Xinhua Hospital.
- Dong D. (July 21, 2024). Exploring the needs of rare disease patients outside of medical arena and related ethical challenges. 2024 Rare Disease Symposium on Collaboration and Communication, Beijing, China. Invited by the Illness Challenge Foundation.
- Dong D. (June 15, 2024). A decade of efforts: A review of real-world data research based on Aili’s Myasthenia Gravis Patient Registry. The 6th China Myasthenia Gravis Patient Conference, Beijing, China. Invited by Beijing Aili Myasthenia Gravis Care Center.
- Dong D. (May 24, 2024). Manufacturing Hope for the Rare Disease Community: Advanced Therapies and the Ethics of Care. 2024 Global Rare Diseases Research Symposium & The Second China Rare Diseases Research and Translational Medicine Annual Conference, Shanghai, China. Invited by Hope For Rare Foundation, International Rare Diseases Research Consortium, and Fudan University.
- Dong D. (February 25, 2024). Leveraging Patient-Reported Outcomes in Patient Registries for Enhanced Real-World Evidence. Hong Kong Pharmacy Conference 2024. Hong Kong. Invited by Hong Kong Pharmacist Association.
- Dong D. (November 11, 2023). How can Hong Kong learn from the Mainland's rare disease policies and implementations and proactively address the challenge of rare diseases? Rare Disease Symposium 2023. Hong Kong. Invited by Rare Disease Hong Kong.
- Dong D. (May 11, 2022). International views/Challenging Cases. Presented at the 14th MGFA International Conference on Myasthenia and Related Disorders (May 10-12, 2022). Invited by Myasthenia Gravis Foundation of America. Miami, Florida, USA.
- Dong D. (December 19, 2021).The development and value of rare disease patient organizations in China. Presented at the 2021 China Conference on Rare Diseases (Dec 18-19, 2021). Invited by China Alliance for Rare Diseases, Beijing, China
- Dong D. (October 1, 2021). The living conditions of Chinese patients with Scleroderma. Presented at the 4th China Scleroderma Conference (Oct 1-2, 2021). Invited by the Chinese Organization for Scleroderma, Chengdu, Sichuan, China.
- Dong D. (September 25, 2021). Measures taken by the Central Government to deal with rare diseases – inspiration to Hong Kong. Presented at the Rare Disease Symposium 2021: Tackling Differences and Implementing Equity (Sept. 25, 2021). Invited by Rare Disease Hong Kong, Hong Kong.
- Wong-Rieger, D., Malherbe H., Janampa, EL, and Dong D. (August 12, 2021). Finding rare diseases in common places: The role of primary care in detection and diagnosis. Webina, Science/AAAS Custom Publishing Office. https://www.science.org/content/webinar/finding-rare-diseases-common-places-role-primary-care-detection-and-diagnosis
- Dong D. (May 16, 2021). General Social Survey on Patients with Wilson Disease in China. Presented at The 1st China Wilson Disease Diagnosis and Development Conference (May 16, 2021). Invited by Chinese organization for Wilson Disease, Hangzhou, Zhejiang, China.
- Dong D. (August 22, 2021). The living conditions of EB patients in China. Presented at the 2021 National EB Patient Conference and “Report on the Living Conditions of EB Patients in China” Press Conference (Aug 22, 2021). Invited by China Debra, Shanghai, China
- Dong D. (February 28, 2021) Roundtable on Drugs for Rare Diseases in Hong Kong. Invited by Rare Disease Hong Kong.
- Dong D. (February 25, 2021) Gender and Disability Issues in Current Health Related Rights Movement - Taking Rare Diseases as an Examples. Invited by the Faculty of Law, University of Hong Kong.
- Dong D. (January 15, 2021). Rare disease & Equity in China: Research Findings & Reflections. Centre for Health Systems and Policy Research (CHSPR) and Institute of Health Equity (IHE), The Chinese University of Hong Kong.
- Dong D. (November 28, 2020) General Social Survey of Chinese Patients with Multiple Scoliosis. Presented at the 1st Symposium on Multiple Scoliosis Diagnosis and Medical Insurance (November 28, 2020).Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (October 25, 2020). Interpreting the report on the living conditions of Chinese patients with rare diseases. Presented at the 2020 China Conference on Rare Diseases (Oct 24-25, 2020). Invited by China Alliance for Rare Diseases, Beijing, China
- Dong D. (August 23, 2020). The Living Conditions of Patients of Lysosomal Storage Diseases in China. 2020 Rare Disease Symposium on Collaboration and Communication. Invited by the Illness Challenge Foundation, Beijing, China
- Dong D. (August 22, 2020). The currency and challenges of multi-party payment models in China: Insights from the national rare disease patient survey. 2020 Rare Disease Symposium on Collaboration and Communication. Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (July 27, 2020). The Economic Burden and Healthcare Needs of Patients with Type I Diabetes. A Seminar on the Payment Innovation of Orphan Drugs and Products. Invited by Beijing Society of Rare Disease Clinical Care and Accessibility, Beijing China.
- Dong D. (June 13, 2020). Interpretation of the whitepaper of Chinese patients with Acromegaly. Presented at the White Paper Conference on the General Social Survey of Chinese Patients with Acromegaly. Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (June 4, 2020). Living status and disease burden of patients with rare diseases in Zhejiang Province: Analysis based on the 2019 general social survey. Presented at the 2020 Zhejiang Rare Disease Symposium on Linking Health and Social Care. Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (April 10, 2020). Three challenges to rare disease patient organizations: Evidences from data. Presented at the Launching Ceremony of “The Rare Challenge: Public Interest Innovation Competition for Rare Disease Patient Organizations.” Invited by the Illness Challenge Foundation, live-streamed.
- Dong D. (December 28, 2019). A national survey of patients with Gaucher Disease: Based on a comparative perspective of medication history. Presented at the 4th China Gaucher Disease Conference. Invited by China Gaucher Disease Association and Illness Challenge Foundation, Beijing, China.
- Dong D. (December 27, 2019). The living conditions and disease burden f patients with rare diseases in Jiangsu Province. Presented at the Founding Meeting of the Rare Diseases Branch of Jiangsu Medical Association and the First Rare Disease Academic Conference in Jiangsu Province (December 26-27, 2019). Invited by the Jiangsu Medical Association, Nanjing, China.
- Dong D. (November 2, 2019). A preliminary investigation into the payments and disease burden of rare diseases patients in China. Presented at the First Conference on Chinese Physician and Public Interest (November 1-3, 2019). Invited by Beijing Life Oasis Public Service Center, Wuxi, China.
- Dong D. (October 19, 2019). The General Social Survey of People Affected by Rare Disease in China – Stage One Report. Presented at the 2019 China Conference on Rare Diseases (Oct 19-20, 2019). Invited by China Alliance for Rare Diseases, Beijing, China.
- Dong D. (July 6, 2019). The importance of patient reported outcomes to policymaking on rare diseases: Empirical evidences from China. Presented at the 2019 Rare Disease Symposium on Collaboration and Communication (July 6-7, 2019). Invited by The China Alliance for Rare Diseases, The Illness Challenge Foundation and The Peking Union Medical College Hospital, Beijing, China.
- Dong D. (May 26, 2019). What shall we do when there is a hope to have a national policy on rare diseases? Presented at the Collaboration Camp for People affected by MS. Invited by the Program on Multiple Sclerosis, the Illness Challenge Foundation, Beijing, China.
- Dong D. (May 25, 2019). Studying rare diseases from a sociological perspective: Data, field and reflections. Invited by the Peking Union Medical College Hospital. Beijing, China.
- Dong D. (April 6, 2019). Rare disease and Orphan drug policies in China: New development. Presented at the Training Camp for Patients and Families Affected by Lysosomal Storage Diseases. Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (July 15 & 16, 2018). Rare disease and Orphan drug policies in China: New development. Invited by the Illness Challenge Foundation to deliver two lectures for patients and families affected by Lysosomal storage diseases, Beijing, China.
- Dong D. (January 6-7, 2018). “Rare disease policy development: Domestic and international experience”, and “Survey and how it can benefit rare disease community”. Invited by the Illness Challenge Foundation to deliver two lectures for patients and families affected by Lysosomal storage diseases, Hefei, Anhui, China.
- Dong D. (November 16, 2017). The rarity Paradox: How to define ‘rare disease’ in the world’s most populous country? Presented at the LEWI Public Seminar, Hong Kong Baptist University, Hong Kong.
- Dong D. (September 11, 2017). The development of rare disease policies in China. Presented at the 2017 Asia Patient Group Exchange Meeting. Invited by the Illness Challenge Foundation, Beijing, China.
- Dong D. (June 15, 2016). Advocating policy change for patients with rare disorders. Presented at the Second National Convention for Patients with Myasthenia Gravis in China (June 15-18, 2016). Invited Aili Myasthenia Gravis Care Center, Beijing, China.
Selected refereed conference proceedings and presentations related to rare diseases
- Dong, D., Wang, J., Zhu, J., Jin, J., Fu, X., Yu, S., Wang, Y. and Wang, C.,(2020). PRO14 Quality of Life in Patients with Gaucher Disease and Factors Associated: A Study on Adult Patients in China. Value in Health Regional Issues, 22, p.S97.https://doi.org/10.1016/j.vhri.2020.07.509
- Dong, D., Chen, S., WU, Y., Zhu, J., Jin, J., Wang, Y. and Guo, P., (2020). PRO7 Economic Burden of Pompe Disease in China: Empirical Evidences and Simulation of Policy Effects. Value in Health Regional Issues, 22, p.S96. https://doi.org/10.1016/j.vhri.2020.07.502
- Wang, J., Dong, D., Zhu, J., Jin, J., Fu, X., Yu, S., Wang, Y. and Wang, C., 2020. PRO76 caregiver-proxy eq-5d ratings of children with gaucher disease: A comparison of 5 domains between genders. Value in Health, 23, p.S342.https://doi.org/10.1016/j.jval.2020.04.1297
- Perceptions on genomic medicine development in Hong Kong: A qualitative study. In APHA 2023 Annual Meeting and Expo. APHA 2023, November 12-15, 2023, Atlanta, GA, USA. (with Fu Faustina Yip, Ka Hei Leung, Samuel Yuk Ching Sze, Ka Yu Wong, and Kailu Wang) https://apha.confex.com/apha/2023/meetingapp.cgi/Paper/529291
- Coping with Unemployment for Disabled People: Care as a Form of Moral empowerment. Oral presentation at the XX ISA World Congress of Sociology, Melbourne, Australia, June 25-July 1, 2023. (with Zhilan Fang, Gabriel Liu, and Liling Zhu)
- Technologies of Unknowing: Navigating Medical Uncertainties as a Moral Bio-Citizen Distributed paper presentation at the XX ISA World Congress of Sociology, Melbourne, Australia, June 25-July 1, 2023. (with Zhilan Fang, Liling Zhu, and Jiazhou Yu)
- Social support and medication compliance among myasthenia gravis patients in China: mediating role of mental health and self-efficacy. Poster presentation at the World Congress on Public Health (WCPH), World Federation of Public Health Associations (WFPHA), May 2-6, 2023, Rome Italy. (with Jiazhou Yu, Luyao Xie, Huanyu zhang, Zhilan Fang, and Richard H. Xu)
- Change in quality of life in adults with late-onset Pompe disease receiving under-dose of enzyme replacement therapy in a nationwide registry: a retrospective matched cohort study from China. Poster presentation at the World Congress on Public Health (WCPH), World Federation of Public Health Associations (WFPHA), May 2-6, 2023, Rome Italy. (with Huanyu Zhang, Shanquan Chen, Richard H. Xu and Jiazhou Yu)
- Doing “Gendered Exit:” Work, Care, and the Moral Practices of People with Disabilities. Presented at the Sociologists for Women in Society Summer Meeting 2022, August 5-9, 2022, Los Angeles, CA (with Zhilan Fang and Liling Zhu).
- Economic Burden of Pompe Disease in China- Empirical Evidences and Simulation of Policy Effects. Presented at the Virtual ISPOR Asia Pacific 2020, 14-16 September 2020. (with Chen S, Wu Y, Zhu J, Jin J, Wang Y, and Guo P).
- Quality of Life in Patients with Gaucher Disease and Factors Associated: A Study on Adult Patients in China. Presented at the Virtual ISPOR Asia Pacific 2020, 14-16 September 2020. (with Wang J, Zhu J, Jin J, Fu X, Yu S, Wang Y, and Wang C).
- The Societal IMPACT of Obinutuzumab in the First-LINE Treatment of Follicular Lymphoma in China. Presented at the Virtual ISPOR Asia Pacific 2020, 14-16 September 2020. (with Wu J, Gu H, Buhrer C, et al)
- The value of adding a bleeding dimension to the EQ-5D-5L in patients with hemophilia. Accepted by the 2nd EuroQol Asia Academic Meeting 2020, 15-16 June 2020, Bali, Indonesia. (with Xu H, Wong ELY, Zhang SY, et al.)
- Caregiver-proxy eq-5d ratings of children with Gaucher Disease: A comparison of 5 domains between genders. Accepted by ISPOR 2020 (with Wang JX, Zhu JF, Jin J, Fu XH, Yu SY, Wu YS, Wang YO, and Wang C)
- Gender Differences in Quality of Life among Mayasthenia Gravis Patients in China. Oral presentation at the 14th Meeting of International Conference on Rare Disease and Orphan Drugs (ICORD), 11-13 November, 2019, Rishon Lezion, Israel. (with Yu SY, Zhu JF, Gu HG, Xu H, and Liu J)
- Economic burden of Pompe disease in China: Empirical evidences and simulation of policy effects. To be presented at the ISPOR Europe 2019. Poster session. Copenhagen, Denmark, Nov 2-6, 2019. (with Chan SQ, Zhu JF, Jin J, Wang YO, and Guo PH)
- Quality of life and its contributors among adults with Pompe disease in China. Presented at the ISPOR 2019, New Orleans, USA. May 18-22, 2019. (with Chan SQ, Zhu JF, Jin J, Wang YO, and Guo PH)
- When “Chicken Talks to Duck”, How to Build Trust in Prenatal Genetic Counseling? - Ethnographic Evidence from Shanghai. The 11th International Convention of Asia Scholars. Leiden, Netherland, July 16-19, 2019. (with Zhu JF)
- Yousheng Policies and technologies: Population quality control in contemporary urban China. Society for Social Studies of Science Annual Conference, Sydney, Australia, August 29-September 1, 2018
- Perceptions of informed choice in prenatal genetic testing: Views from women in China. International Society for Prenatal Diagnosis (ISPD) annual conference, Antwerp, Belgium, July 8- 11, 2018. (with Rui Zhao and Jianfeng Zhu).
- Training communication in genetic counseling: Peer observed interaction, structured evaluation, and ethnographic reflexivity. The 68th International Communication Association Annual Conference, Health Communication Division, Prague, Czech Republic, May 24-28, 2018. (With Xiong Shiyi and Zhu Jianfeng).
- Rare, and unfair: social disparities and health inequity experienced by people with rare diseases in urban and rural China. International Conference on Polarisation, Fragmentation and Resilience: Four Urban Contexts Compared, Hong Kong, November 29 – December 1, 2017.
- The unbearable weight of being rare: Results from the first national survey among people living with rare diseases in China. Rare Disease and Orphan Products Breakthrough Summit 2017, Washington DC, USA, October 15-17, 2017.
- Peer Observed Interaction, Structured Evaluation, and Ethnographic Reflexivity: A mixed-method study on a genetic counseling training course in China. The 12th Annual International Conference on Rare Diseases and Orphan Drugs & the 6th China Rare Disease Summit, Beijing, China, September 7-10, 2017. (With Xiong Shiyi and Zhu Jianfeng).
- Diagnosis and treatment of rare diseases in general hospitals: Preliminary results from a survey study in China. The 12th Annual International Conference on Rare Diseases and Orphan Drugs & the 6th China Rare Disease Summit, Beijing, China, September 7-10, 2017. (With Song Hai, Feng Meizhu, Jiu Jinyan, Si Hongwei, and Xie Bingjie).
- Living or surviving? The medical, social and economic conditions of people affected by rare diseases in China. The Tenth International Convention of Asia Scholars. Chiang Mai, Thailand, July 20-23, 2017.
- Two Stones, One Bird: Patient Organizations and Rare Disorder Policymaking in China. The 2016 American Anthropology Association Annual Meeting, Minneapolis, Minnesota, USA, November 16-20, 2016.
- The economic burden and its consequences on families with children affected by Myasthenia Gravis in China. The 8th European Conference on Rare Diseases & Orphan Products (ECRD) 2016, Edinburgh, UK, May 26-28, 2016. (With Liu Ji)
External Service
NGO Board member
- Asian Pacific Alliance of Rare Disease Organisations (APARDO), 2024-present
- China Alliance for Rare Diseases (The only semi-official national rare disease organization Approved by the National Health Commission), 2020-present
- Beijing Society of Rare Disease Clinical Care and Accessibility, 2020-present
- The Illness Challenge Foundation (The largest national umbrella rare disease patient organization in China), 2021-present
- Beijing Aili Myasthenia Gravis Care Center (A National patient organization on Myasthenia Gravis), 2018-present
Patient Organization Advisory Committee
- Rare Disease Hong Kong (RDHK), Member of the Scientific and Medical Advisory Committee (SMAC) 2022-present
- Cancer Patient Alliance Hong Kong, Consultant, 2021-present
Knowledge Transfer Activities
Public education & Newspaper commentaries
- 董咚. 沒有人能在“獨善其身”中安然無恙。奴隸社會, 28/02/2025. 閱讀量1.3萬
- 董咚. 冰桶挑戰十周年:香港罕見病政策之倫理思考。信報, 06/01/2025
- 董咚.孤兒藥:從藥廠棄兒到莎樂美腸策略。知識分子, 28/02/2022. 閱讀量1.3萬
- 董咚. 因為罕見,所以驕傲。奴隸社會, 28/02/2021. 閱讀量8萬
Selected media interviews
- 2024/02/29, Crystal Chow, A Moonshot to Cure Angelman Syndrome is Reachable. Where are the People Counting on It? Link
- 2017/08/06, 文匯報 A12, 中國新聞台海新聞.調查:逾五成受訪「瓷娃娃」求學被拒 患者及家屬聚深分享經歷120病友接受義診
- 2017/08/08, 廣州日報(深圳版)], 深圳新聞. 瓷娃娃”全國病友大會上周末在深舉行 過半“瓷娃娃”求學曾被拒 大二“瓷娃娃”變“鋼鐵俠”
- 2018/03/06, 新京報 D04 | 健康周刊·新圖紙. 六成以上罕見病患者被誤診過《2018中國罕見病調研報告》顯示,病友平均需承擔近八成醫療開支,超三成醫生不了解罕見病
Selected invited presentations/lectures on rare disease
- (July 24, 2024) Disease management and quality of life among SMA patients in China: Findings based on Meier SMA patient registry.
- (July 21, 2024) Exploring the needs of rare disease patients outside of medical arena and related ethical challenges.
- (June 15, 2024) A decade of efforts: A review of real-world data research based on Aili's Myasthenia Gravis Patient Registry.
- (May 24, 2024) Manufacturing Hope for the Rare Disease Community: Advanced Therapies and the Ethics of Care.
- (February 25, 2024) Leveraging Patient-Reported Outcomes in Patient Registries for Enhanced Real-World Evidence.
- (November 11, 2023) How can Hong Kong learn from the Mainland's rare disease policies and implementations and proactively address the challenge of rare diseases?
- (May 11, 2022) International views/Challenging Cases.
- (December 19, 2021) The development and value of rare disease patient organizations in China.
- (October 1, 2021) The living conditions of Chinese patients with Scleroderma.
- (September 25, 2021) Measures taken by the Central Government to deal with rare diseases – inspiration to Hong Kong.
- (August 12, 2021) Finding rare diseases in common places: The role of primary care in detection and diagnosis.
- (May 16, 2021) General Social Survey on Patients with Wilson Disease in China.
- (August 22, 2021) The living conditions of EB patients in China.
- (February 28, 2021) Roundtable on Drugs for Rare Diseases in Hong Kong.
- (February 25, 2021) Gender and Disability Issues in Current Health Related Rights Movement.
- (January 15, 2021) Rare disease & Equity in China: Research Findings & Reflections.
- (November 28, 2020) General Social Survey of Chinese Patients with Multiple Sclerosis.
- (October 25, 2020) Interpreting the report on the living conditions of Chinese patients with rare diseases.
- (August 23, 2020) The Living Conditions of Patients of Lysosomal Storage Diseases in China.
- (August 22, 2020) The currency and challenges of multi-party payment models in China.
- (July 27, 2020) The Economic Burden and Healthcare Needs of Patients with Type I Diabetes.
- (June 13, 2020) Interpretation of the whitepaper of Chinese patients with Acromegaly.
- (June 4, 2020) Living status and disease burden of patients with rare diseases in Zhejiang Province.
- (April 10, 2020) Three challenges to rare disease patient organizations.
- (December 28, 2019) A national survey of patients with Gaucher Disease.
- (December 27, 2019) The living conditions and disease burden f patients with rare diseases in Jiangsu Province.
- (November 2, 2019) A preliminary investigation into the payments and disease burden of rare diseases patients in China.
- (October 19, 2019) The General Social Survey of People Affected by Rare Disease in China – Stage One Report.
- (July 6, 2019) The importance of patient reported outcomes to policymaking on rare diseases.
- (May 26, 2019) What shall we do when there is a hope to have a national policy on rare diseases?
- (May 25, 2019) Studying rare diseases from a sociological perspective.
- (April 6, 2019) Rare disease and Orphan drug policies in China: New development.
- (July 15 & 16, 2018) Rare disease and Orphan drug policies in China: New development (Lectures).
- (January 6-7, 2018) Rare disease policy development (Lectures).
- (November 16, 2017) The rarity Paradox: How to define ‘rare disease'.
- (September 11, 2017) The development of rare disease policies in China.
- (June 15, 2016) Advocating policy change for patients with rare disorders.
Selected refereed conference proceedings and presentations related to rare diseases
- (2020) PRO14 Quality of Life in Patients with Gaucher Disease and Factors Associated: A Study on Adult Patients in China.
- (2020) PRO7 Economic Burden of Pompe Disease in China: Empirical Evidences and Simulation of Policy Effects.
- (2020) PRO76 caregiver-proxy eq-5d ratings of children with gaucher disease: A comparison of 5 domains between genders.
- (Nov 2023) Perceptions on genomic medicine development in Hong Kong: A qualitative study.
- (June-July 2023) Coping with Unemployment for Disabled People: Care as a Form of Moral empowerment.
- (June-July 2023) Technologies of Unknowing: Navigating Medical Uncertainties as a Moral Bio-Citizen.
- (May 2023) Social support and medication compliance among myasthenia gravis patients in China.
- (May 2023) Change in quality of life in adults with late-onset Pompe disease receiving under-dose of enzyme replacement therapy.
- (Aug 2022) Doing "Gendered Exit:” Work, Care, and the Moral Practices of People with Disabilities.
- (Sept 2020) Economic Burden of Pompe Disease in China - Empirical Evidences and Simulation of Policy Effects.
- (Sept 2020) Quality of Life in Patients with Gaucher Disease and Factors Associated.
- (Sept 2020) The Societal IMPACT of Obinutuzumab in the First-LINE Treatment of Follicular Lymphoma in China.
- (June 2020) The value of adding a bleeding dimension to the EQ-5D-5L in patients with hemophilia.
- (2020) Caregiver-proxy eq-5d ratings of children with Gaucher Disease: A comparison of 5 domains between genders.
- (Nov 2019) Gender Differences in Quality of Life among Mayasthenia Gravis Patients in China.
- (Nov 2019) Economic burden of Pompe disease in China: Empirical evidences and simulation of policy effects.
- (May 2019) Quality of life and its contributors among adults with Pompe disease in China.
- (May 2019) When “Chicken Talks to Duck”, How to Build Trust in Prenatal Genetic Counseling?
- (July 2019) Yousheng Policies and technologies: Population quality quality control in contemporary urban China.
- (July 2019) Perceptions of informed choice in prenatal genetic testing: Views from women in China.
- (May 2018) Training communication in genetic counseling: Peer observed interaction, structured evaluation, and ethnographic reflexivity.
- (Nov 2017) Rare, and unfair: social disparities and health inequity experienced by people with rare diseases in urban and rural China.
- (Oct 2017) The unbearable weight of being rare: Results from the first national survey among people living with rare diseases in China.
- (Sept 2017) Peer Observed Interaction, Structured Evaluation, and Ethnographic Reflexivity.
- (Sept 2017) Diagnosis and treatment of rare diseases in general hospitals.
- (July 2017) Living or surviving? The medical, social and economic conditions of people affected by rare diseases in China.
- (Nov 2016) Two Stones, One Bird: Patient Organizations and Rare Disorder Policymaking in China.
- (May 2016) Myasthenia Gravis in China.